Increasing Inclusion of Participants, Leveraging Gut Microbiomes, and Optimizing Machine Learning Models to Advance Warfarin Precision Medicine
Year: 2022
Type: dissertation
Abstract: Precision medicine, one of the promises of the future of clinical medicine, will not be realized without challenges. Here, focusing on an individual pharmaceutical therapeutic, warfarin, we demonstrate idealistic benefits, realistic caveats, and paths to improving the benefits and equity of precision medicine through rigorous research. Anticoagulation therapy with the popular vitamin K antagonist, warfarin, can be challenging due to large interpatient dose variability and a narrow therapeutic window. Warfarin genotype-guided dose prediction models currently can account for approximately 50% of the total variability seen across patients, however, this number can also be as low as 20% in diverse populations. This lack of equity and overall dismal performance of genotype-guided dosing has reasonably slowed the clinical implementation of warfarin dose predictions models and is a driving force of the research projects presented here. The paths that we suggest for improving future benefits of precision medicine research: 1) consciously include everyone, 2) survey the environment, regardless of temporal stability, and 3) validate the generalizations we make. In this thesis we briefly introduce the fields of pharmacogenetics, pharmacomicrobiomics, and statistical modeling to provide evidence for each of the previous suggestions demonstrated by the attached appendices. Finally, we make predictions regarding the future of warfarin precision medicine.
Authors: Steiner, Heidi, Steiner, Heidi
Language: English
Subfield: Pharmacology
Domain: Life Sciences
Open Access status: green
Funders: University of Arizona, Fundação de Amparo à Pesquisa do Estado de São Paulo, Coordenação de Aperfeiçoamento de Pessoal de Nível Superior, Conselho Nacional de Desenvolvimento Científico e Tecnológico, National Institutes of Health, National Heart, Lung, and Blood Institute, National Institute of Environmental Health Sciences, National Center for Advancing Translational Sciences, National Institute on Minority Health and Health Disparities
Awards: G1886917252, G295657101, G4080271223, Pharmacogenomics: implementation and cost-effectiveness evaluation, A Genomic Approach to Warfarin Dose Prescription in Admixed Caribbean Hispanics., Pharmacogenetic of cardiovascular system drugs focusing on implementation, Genomic and Transcriptomic Influences on Heparin-Induced Thrombocytopenia, G9000072640, Training in Environmental Toxicology of Human Disease, Leveraging the Microbiome, Local Admixture, and Machine Learning to Optimize Anticoagulant Pharmacogenomics in Medically Underserved Patients, ABO and Immunogenetic Variation in the Pathogenesis of Heparin-Induced Thrombocytopenia
OpenAlex ID: W7019951360
